©TELIX – None of Telix’s product pipeline has received marketing authorization in any jurisdiction. Any use of Telix products is on an investigational basis or for use in approved clinical trials. TLX250 (Lu-177-DOTA-girentuximab) is a therapeutic Radiopharmaceutical that uses anti-CAIX girentuximab (just like the Imaging application) to deliver a therapeutic dose of targeted Radiation to clear cell renal cell carcinoma (ccRCC)
What is it?
Kidney cancer is a disease where abnormal cells grow out of control in one or both kidneys. It can affect adults and children. The most common type is renal cell carcinoma (RCC), making up about 90% of adult kidney cancers. RCC starts in the lining of the small tubes inside the kidney.
There are different subtypes of RCC, including:
- Clear cell RCC – the most common form
- Papillary RCC – has two subtypes and tends to grow slower
- Chromophobe RCC – a rare form that usually grows slowly
Other, less common kidney cancer types include:
- Transitional cell carcinoma (urothelial carcinoma) – starts in the area where the kidney connects to the ureter
- Renal sarcoma – a rare cancer that forms in the kidney’s connective tissues
- Wilms tumor – a kidney cancer seen mostly in children
Understanding the type of kidney cancer is important because it helps guide the most effective treatment.
Main Symptons
Early-stage kidney cancer often has no warning signs. As it grows, symptoms may include:
- Blood in the urine
- Persistent pain in the side or back
- A lump in the abdomen
- Unexplained weight loss or feeling unwell
Standard treatments
Treatment depends on how far the cancer has spread:
- Surgery is common, either removing part (partial nephrectomy) or all of the kidney (radical nephrectomy).
- Radiation therapy uses high-energy rays to kill cancer cells;may help relieve symptoms when surgery isn’t an option.
- Immunotherapy helps the immune system fight the cancer.
- Targeted drugs uses special drugs that attack specific parts of cancer cells, responsible for the cancer growth or survival; sparing most healthy cells.
Radiotheranostics
Radiotheranostics is a new type of treatment that combines therapy and diagnostics. Currently there are no approved radiotheranostics for kidney cancer.
Many companies are conducting clinical trials as shown below.
Your doctor can help you understand which treatment is right for you
To know more about:
Patient associations
Europe: A.R.Tu.R (FRA)
North America: National Kidney Foundation (USA)
Worldwide: International Kidney Cancer Coalition (IKCC)